Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3610399rdf:typepubmed:Citationlld:pubmed
pubmed-article:3610399lifeskim:mentionsumls-concept:C0006383lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0004238lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0002598lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0085973lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0007320lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C0457405lld:lifeskim
pubmed-article:3610399lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:3610399pubmed:issue1lld:pubmed
pubmed-article:3610399pubmed:dateCreated1987-8-28lld:pubmed
pubmed-article:3610399pubmed:abstractTextWe observed a dangerous increase of ventricular rate following the intravenous administration of amiodarone in a patient with atrial fibrillation and rapid ventricular response associated with the Wolff-Parkinson-White syndrome. The mechanism of enhanced accessory pathway conduction remains speculative. A possible explanation for the shortened antegrade effective refractory period of the accessory pathway is afforded by the hypotensive action of amiodarone or its dissolvent which might trigger beta-adrenergic reflexes. Intravenous amiodarone should be used with caution in patients with atrial fibrillation and rapid ventricular response via an accessory pathway.lld:pubmed
pubmed-article:3610399pubmed:languageenglld:pubmed
pubmed-article:3610399pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3610399pubmed:citationSubsetIMlld:pubmed
pubmed-article:3610399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3610399pubmed:statusMEDLINElld:pubmed
pubmed-article:3610399pubmed:monthJullld:pubmed
pubmed-article:3610399pubmed:issn0167-5273lld:pubmed
pubmed-article:3610399pubmed:authorpubmed-author:GmeinerRRlld:pubmed
pubmed-article:3610399pubmed:authorpubmed-author:LeischFFlld:pubmed
pubmed-article:3610399pubmed:authorpubmed-author:Schützenberge...lld:pubmed
pubmed-article:3610399pubmed:issnTypePrintlld:pubmed
pubmed-article:3610399pubmed:volume16lld:pubmed
pubmed-article:3610399pubmed:ownerNLMlld:pubmed
pubmed-article:3610399pubmed:authorsCompleteYlld:pubmed
pubmed-article:3610399pubmed:pagination93-5lld:pubmed
pubmed-article:3610399pubmed:dateRevised2006-7-12lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:meshHeadingpubmed-meshheading:3610399-...lld:pubmed
pubmed-article:3610399pubmed:year1987lld:pubmed
pubmed-article:3610399pubmed:articleTitleEnhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report.lld:pubmed
pubmed-article:3610399pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3610399pubmed:publicationTypeCase Reportslld:pubmed